SCHEMBL3915495

SCHEMBL3915495

CCC(=O)ON=C=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28178839 0.82
SCHEMBL21315579 0.78
SCHEMBL13644133 0.76
SCHEMBL29047895 0.74 ALDH1A1 (0.31)
SCHEMBL27659815 0.73
SCHEMBL18683009 0.72
SCHEMBL3382447 0.72
SCHEMBL9363944 0.71
Ethane SCHEMBL10979758 0.70
SCHEMBL9243517 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1990477-A Linear dicationic terphenyls and their aza analogues as antiparasitic agents UNIV NORTH CAROLINA CHAPEL HILL (US) 2007-07-04 CN claimed
CN-115403584-B 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-117440953-A Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors 苏州浦合医药科技有限公司 2024-01-23 CN disclosed
CN-115403584-A 2-thio-2, 3-dihydropyrimidine-4-one derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-11-29 CN disclosed
CN-112531211-B Electrolyte, preparation method thereof and lithium ion battery 惠州亿纬锂能股份有限公司 2022-06-14 CN disclosed
CN-112531211-A Electrolyte, preparation method thereof and lithium ion battery 惠州亿纬锂能股份有限公司 2021-03-19 CN disclosed
US-20140179711-A1 PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-26 US disclosed
US-8680103-B2 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-25 US disclosed
EP-1711481-B2 CRYSTALLINE MONOHYDRATE AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-05-22 EP disclosed
US-20120302750-A1 PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-11-29 US disclosed
US-6525052-B2 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-02-25 US disclosed
WO-2002100327-A2 SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF ANTEXPHARMA, INC. (US) 2002-12-19 WO disclosed
US-20020137932-A1 Novel compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-09-26 US disclosed
US-6420364-B1 TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-07-16 US disclosed
EP-1218372-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES Boehringer Ingelheim Pharmaceuticals, Inc. (US) 2002-07-03 EP disclosed
US-20020058809-A1 Compounds useful as reversible inhibitors of cysteine proteases EMMANUEL MICHEL JOSE (US) 2002-05-16 US disclosed
WO-2002020485-A1 SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-03-14 WO disclosed
CN-1072647-C Novel inhibitors of bone resorption and antagonists of vitronectin receptors HOECHST AG (DE) 2001-10-10 CN disclosed
WO-2001019816-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2001-03-22 WO disclosed
CN-1206005-A Novel inhibitors of bone resorption and antagonists of vitronectin receptors HOECHST AG (DE) 1999-01-27 CN disclosed